Sanofi's Myqorzo & Redemplo

Paris, January 15, 2026, the National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control.
From Sanofi

Olivier Charmeil, Executive Vice President, General Medicines, Sanofi, Said, “We are pleased to bring Myqorzo and Redemplo to patients in Greater China. Both medicines represent important advances in treatment options and address unmet medical needs among people living . . .